OncoScint (Cytogen Corp, Lonza Biologics)
OncoScint (Cytogen Corp, Lonza Biologics) Brand names, OncoScint (Cytogen Corp, Lonza Biologics) Analogs
OncoScint (Cytogen Corp, Lonza Biologics) Brand Names Mixture
- No information avaliable
OncoScint (Cytogen Corp, Lonza Biologics) Chemical_Formula
C6268H9708N1666O1971S48
OncoScint (Cytogen Corp, Lonza Biologics) RX_link
No information avaliable
OncoScint (Cytogen Corp, Lonza Biologics) fda sheet
OncoScint (Cytogen Corp, Lonza Biologics) msds (material safety sheet)
OncoScint (Cytogen Corp, Lonza Biologics) Synthesis Reference
No information avaliable
OncoScint (Cytogen Corp, Lonza Biologics) Molecular Weight
141478.9
OncoScint (Cytogen Corp, Lonza Biologics) Melting Point
61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
OncoScint (Cytogen Corp, Lonza Biologics) H2O Solubility
No information avaliable
OncoScint (Cytogen Corp, Lonza Biologics) State
Liquid
OncoScint (Cytogen Corp, Lonza Biologics) LogP
-0.427
OncoScint (Cytogen Corp, Lonza Biologics) Dosage Forms
No information avaliable
OncoScint (Cytogen Corp, Lonza Biologics) Indication
For diagnosis of extrahepatic malignant cancers
OncoScint (Cytogen Corp, Lonza Biologics) Pharmacology
Binds to the tumor associated glycoprotein 72 antigen, which is a cell surface protein generally over-expressed in colorectal cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of TAG-72 expressing cells and tumors
OncoScint (Cytogen Corp, Lonza Biologics) Absorption
No information avaliable
OncoScint (Cytogen Corp, Lonza Biologics) side effects and Toxicity
No information avaliable
OncoScint (Cytogen Corp, Lonza Biologics) Patient Information
No information avaliable
OncoScint (Cytogen Corp, Lonza Biologics) Organisms Affected
No information avaliable
